Menu Back toDoes-Sourcing-Strategy-Matter-Executives-Debate-the-Influence-of-Outsourcing-Model-on-Clinical-Trial-Execution

DIA 2018 Global Annual Meeting


Does Sourcing Strategy Matter? Executives Debate the Influence of Outsourcing Model on Clinical Trial Execution

    Session Chair(s)
      Mitchell A. Katz, PhD

      Mitchell A. Katz, PhD

      • Head of Clinical Research and Drug Safety Operations
      • Purdue Pharma L.P., United States
    In this provocative session, executives from various sponsor organizations will react to the 2017 industry report on risk in clinical trials. They will share its 2017 industry findings on the state of clinical outsourcing, risk assessment, and risk-based approaches to managing quality and oversight in the context of a changing regulatory landscape. With a near equal balance of respondents identifying as using primarily FSP or primarily Full-Service models, they will shed light on what the data says about the impact of sourcing model on quality, relationships, and risk-based approaches.Forward-thinking executive leaders from pharma and CRO respondents will respond to the findings with their own interpretations, describe strategies where threats and opportunities may be addressed, and promote their own unique view.
    Learning Objective : Access the data on trial perspectives.
    Speaker(s)
      William J. Sharbaugh, MA, MSc

      Panelist

      William J. Sharbaugh, MA, MSc

      • Chief Operating Officer
      • PPD, United States
      John J. Oidtman

      Panelist

      John J. Oidtman

      • Senior Vice President, Head of Global Clinical Operations
      • EMD Serono, Inc., United States
      Jeremy G. Chadwick, PhD, MSc

      Panelist

      Jeremy G. Chadwick, PhD, MSc

      • Group Vice President, Clinical Development Operations
      • Shire, United States